Cancer Worry in Patients with Hereditary Cancer Syndromes

N
Nawal Kassem

Primary Investigator

Enrolling By Invitation
18 years - 100 years
All
Phase N/A
75 participants needed
3 Locations

Brief description of study

What is the purpose of this study?

The purpose of this study to understand how patients cope with a hereditary cancer diagnosis, and what factors affect, either positively or negatively, the patient’s ability to cope with their diagnosis.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. 
 
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632</div>

Detailed description of study

What will happen during the study?

This is a cross-sectional study focused on patients with hereditary cancer syndrome. All patients seen in medical genetics clinic, high risk clinics, oncology clinics, surgery clinics, or gynecology, and gynecology/oncology clinics who carry a diagnosis of a hereditary cancer syndrome will be eligible for the study. 

After they are enrolled, participants will be asked to complete one study questionnaire. Estimated time for completion is 30-60 minutes. They will be offered iPads to complete the questionnaires via REDCap after their clinical visit, or they may complete the study questionnaires via email, if they prefer. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hereditary cancer syndrome
  • Age: 18 years - 100 years
  • Gender: All

Inclusion criteria:

1.    Age 18 years old or older at time of informed consent

2.    Ability to provide informed consent

3.    Diagnosis of a hereditary cancer syndrome 

Updated on 28 May 2025. Study ID: HEMO-IUSCCC-0918, 26417
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center